Sotera Health Reaffirms 2026 Outlook Amidst European Medical Device Market Softness
Sotera Health (SHC) reported solid year-over-year growth for the third quarter of 2026, characterized by improvements in both top and bottom-line performance. The company achieved a sequential adjusted EBITDA margin improvement of nearly 100 basis points, which CEO Alton Shader attributed to strong operational execution. Despite this internal momentum, the company noted headwinds stemming from softness within the European medical device market. Nevertheless, management has reaffirmed its full-year 2026 outlook, targeting an adjusted earnings per share (EPS) in the range of $0.95 to $1.01.
Tickers: $SHC
Topics: earnings EBITDA margin financial performance revenue growth
Read the full article at Seeking Alpha
Part of the story Sotera Health Reports Q3 2026 Growth Driven by Sterigenics and Nelson Labs (5 articles)